Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors VI. A series of new derivatives containing N,S- and N,SO2-spiro acetal scaffolds

Chemical and Pharmaceutical Bulletin

Volumn 55, Issue 2, 2007, Pages 317-323

  Saitoh, Fumihiko ^a   Nishida, Hidemitsu ^a   Mukaihira, Takafumi ^a   Kosuga, Naoto ^a   Ohkouchi, Munetaka ^a   Matsusue, Tomokazu ^a   Shiromizu, Ikuya ^a   Hosaka, Yoshitaka ^a   Matsumoto, Miwa ^a   Yamamoto, Ichiro ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Factor Xa inhibitor; Intramolecular cyclization; N,S spiro acetal; N,SO2 spiro acetal; Structure activity relationship

Indexed keywords

7 [(6 CHLORO 2 NAPHTHALENYL)SULFONYL]TETRAHYDRO 1' (4 PYRIDINYL)SPIRO(5H THIAZOLO[3,2 A]PYRAZINE 2(3H),4' PIPERIDIN) 5 ONE; 7 [(6 CHLORO 2 NAPHTHALENYL)SULFONYL]TETRAHYDRO 1' (4 PYRIDINYL)SPIRO(5H THIAZOLO[3,2 A]PYRAZINE 2(3H),4' PIPERIDIN) 5 ONE 1,1 DIOXIDE; 7 [(6 CHLORO 2 NAPHTHALENYL)SULFONYL]TETRAHYDRO 8ALPHA (HYDROXYMETHYL) 1' (4 PYRIDINYL)SPIRO(5H THIAZOLO[3,2 A]PYRAZINE 2(3H),4' PIPERIDIN) 5 ONE; 7 [(6 CHLORO 2 NAPHTHALENYL)SULFONYL]TETRAHYDRO 8ALPHA (HYDROXYMETHYL) 1' (4 PYRIDINYL)SPIRO(5H THIAZOLO[3,2 A]PYRAZINE 2(3H),4' PIPERIDIN) 5 ONE 1,1 DIOXIDE; 7 [(6 CHLORO 2 NAPHTHALENYL)SULFONYL]TETRAHYDRO 8ALPHA (METHOXYMETHYL) 1' (4 PYRIDINYL)SPIRO(5H THIAZOLO[3,2 A]PYRAZINE 2(3H),4' PIPERIDIN) 5 ONE; 7 [(6 CHLORO 2 NAPHTHALENYL)SULFONYL]TETRAHYDRO 8ALPHA (METHOXYMETHYL) 1' (4 PYRIDINYL)SPIRO(5H THIAZOLO[3,2 A]PYRAZINE 2(3H),4' PIPERIDIN) 5 ONE 1,1 DIOXIDE; ACETAL DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS;

ACETALS; ANTICOAGULANTS; ANTITHROMBIN III; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NITROGEN; OXYGEN; PIPERIDINES; SERINE PROTEINASE INHIBITORS; SPIRO COMPOUNDS;

EID: 33846968852     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.55.317     Document Type: Article

References (43)

1. Part 1: Nishida H., Miyazaki Y., Kitamura Y., Ohashi M., Matsusue T., Okamoto A., Hosaka Y., Ohnishi S., Mochizuki H., Chem. Pharm. Bull., 49, 1237-1244 (2001).
2. Part 2: Nishida H., Miyazaki Y., Mukaihira T., Saitoh F., Fukui M., Harada K., Itoh M., Muraoka A., Matsusue T., Okamoto A., Hosaka Y., Matsumoto M., Ohnishi S., Mochizuki H., Chem. Pharm. Bull., 50, 1187-1194 (2002).
3. Part 3: Nishida H., Miyazaki Y., Mukaihira T., Shimada H., Suzuki K., Saitoh F., Mizuno M., Matsusue T., Okamoto A., Hosaka Y., Matsumoto M., Ohnishi S., Mochizuki H., Chem. Pharm. Bull., 52, 459-462 (2004).
4. Part 4: Nishida H., Mukaihira T., Saitoh F., Harada K., Fukui M., Matsusue T., Okamoto A., Hosaka Y., Matsumoto M., Shiromizu I., Ohnishi S., Mochizuki H., Chem. Pharm. Bull., 52, 406-412 (2004).
5. Part 5: Saitoh F., Mukaihira T., Nishida H., Satoh T., Okano A., Yumiya Y., Ohkouchi M., Johka R., Matsusue T., Shiromizu I., Hosaka Y., Matsumoto M., Ohnishi S., Chem. Pharm. Bull., 54, 1535-1544 (2006).
6. Hosaka Y., Matsumoto M., Shinozaki M., Ohno T., Yatagai Y., Kamiya M., Kurokawa M., Nishida H., Matsusue T., Mizuguchi K., Ishi H., Eur. J. Pharmacol., 529, 164-171 (2006).
7. Davie E. W., Fujikawa K., Kisiel W., Biochemistry, 30, 10363-10370 (1991).
8. Mann K. G., Nesheim M. E., Church W. R., Haley P., Krishnaswamy S., Blood, 76, 1-16 (1990).
9. Rosenberg J. S., Beeler D. L., Rosenberg R. D., J. Biol. Chem., 250, 1607-1617 (1995).
10. Harker L. A., Hanson S. R., Kelly A. B., Thromb. Haemost., 78, 736-741 (1997).
11. Elodi S., Varadi K., Thromb. Res., 15, 617-629 (1979).
12. Markwardt F., Nowak G., Sturzebecher J., Vogel G., Thromb. Res., 52, 393-400 (1988).
13. Heras M., Chesbro J. H., Penny W. J., Bailey K. R., Badimon L., Fuster V., Circulation, 79, 657-665 (1989).
14. Markwardt F., Thromb. Haemost., 66, 141-152 (1991).
15. Markwardt F., Thromb. Res., 74, 1-23 (1994).
16. Kaplan K. L., Francis C. W., Semin. Hematol., 39, 187-196 (2002).
17. Waxman L., Smith D. E., Arcuri K. E., Vlasuk G. P., Science, 248, 593-596 (1990).
18. Jordan S. P., Waxman L., Smith D. E., Vlasuk G. P., Biochemisyry, 29, 11095-11100 (1990).
19. Neper M. P., Waxman L., Smith D. E., Schulman C. A., Sardana M., Ellis R. W., Schaffer L. W., Siegel P. K. S., Vlasuk G. P., J. Biol. Chem., 265, 17746-17752 (1990).
20. Schaffer L. W., Davidson J. T., Vlasuk G. P., Siegl P. K. S., Circulation, 84, 1741-1748 (1991).
21. Dunwiddie C. T., Neeper M. P., Nutt E. M., Waxman L., Smith D. E., Hofmann K. J., Lumma P. K., Garsky V. M., Vlasuk G. P., Biochemisyry, 31, 12126-12131 (1992).
22. Vlasuk G. P., Thromb. Haemost., 70, 212-216 (1993).
23. Ragosta M., Gimple L. W., Gertz D., Dunwiddie C. T., Vlasuk G. P., Haber H. L., Powers E. R., Roberts W. C., Sarembock I. J., Circulation, 89, 1262-1271 (1994).
24. Fevig J. M., Wexler R. R., Ann. Rep. Med. Chem., 34, 81-100 (1999).
25. Sanderson P. E. J., Med. Res. Rev., 19, 179-197 (1999).
26. Hauptmann J., Sturzebecher J., Thromb. Res., 93, 203-241 (1999).
27. Weitz J. I., Hirsh J., Chest, 119, 95S-107S (2001).
28. Eisenberg P. R., Siegel J. E., Abendschein D. R., Miletich J. P., J. Clin. Invest., 91, 1877-1883 (1993).
29. Kaiser B., Hauptmann J., Cardiovasc. Drug Rev., 12, 225-236 (1994).
30. Prager N. A., Abendschein D. R., McKenzie C. R., Eisenberg P. R., Circulation, 92, 962-967 (1995).
31. Wong P. C., Crain E. J., Jr., Nguan O., Watson C. A., Racanelli A., Thromb. Res., 83, 117-126 (1996).
32. Herault J. P., Bernat A., Pflieger A. M., Lormeau J. C., Herbert J. M., J. Pharmacol. Exp. Ther., 283, 16-22 (1997).
33. Scarborough R. M., J. Enzym. Inhib., 14, 15-25 (1998).
34. Kunitada S., Therap. Res., 19, 7-12 (1998).
35. Petitou M., Duchaussoy P., Jaurand G., Gourvenec F., Lederman I., Strassel J.-M., Bârzu T., Crépon B., Hérault J.-P., Lormeau J.-C., Bernat A., Herbert J.-M., J. Med. Chem., 40, 1600-1607 (1997).
36. Boneu B., Necciari J., Cariou R., Sie P., Gabaig A. M., Kieffer G., Dickinson J., Lamond G., Moelker H., Mant T., Magnani H., Thromb. Haemost., 74, 1468-1473 (1995).
37. Vuillemenot A., Schiele F., Meneveau N., Claudel S., Donat F., Fontecave S., Cariou R., Samama M. M., Bassand J. P., Thromb. Haemost., 81, 214-220 (1999).
38. MOPAC PM3 calculation was used in SYBYL7.1 (Tripos Inc.).
39. Warshawsky A. M., Flynn G. A., WO 9404531 (1994).
40. Fujii N., Yajima H., Chem. Pharm. Bull., 23, 1596-1603 (1975).
41. Nishida H., Mukaihira T., WO 2002053568 (2002).
42. Nishida H., Saitoh F., Harada K., Shiromizu I., WO 2001002397 (2001).
43. 50; 18.2 nM). The overall conformation of compound 18 might be changed by both N-mathylation and without a side chain.